TABLE 2.

Summary of related calcium channels drugs.

Target Ca2+ channels	Agonist/Antagonist	Drugs	Related skin diseases	Potential pharmacologic effect	References
VGCC	Antagonist	Mibefradil	Melanoma	Induced apoptosis, impairs migration	Barcelo et al. (2020)
	Antagonist	Kurtoxin	Melanoma	Reduce viability and proliferation	Das et al. (2012)
	Antagonist	Nifedipine	Skin barrier	Accelerated the barrier recovery	Denda et al. (2006)
	Antagonist	Verapamil	Skin barrier	Accelerated the barrier recovery	Denda et al. (2006)
	Antagonist	R-(+)-BAY K8644	Skin barrier	Accelerated the barrier recovery	Denda et al. (2006)
TRPV1	Antagonist	TIP	Skin ageing	Prevented UV-induced MMP-1 and pro-inflammatory cytokines	Kang et al. (2017)
	Antagonist	PAC-14028 cream	Atopic dermatitis		Lee et al. (2019)
	Antagonist	AG1529	Neurogenic inflammation	Abolished inflammation, reduced neuronal firing	Nikolaeva-Koleva et al. (2021)
	Antagonist	Capsazepine	Itch		Moran, (2018)
	Antagonist	SB-705498	Itch	Influenced neurogenic inflammation	Holland et al. (2014)
ORAI1	Antagonist	Spirodela polyrhiza	Atopic	Inhibited mast cell degranulation	Nam et al. (2017)
TRPV3	Agonist	Extract	Dermatitis	Partially restore the impaired differentiation of keratinocytes	Nam et al. (2017)
TRPC6	Agonist	Hyperforin-containing cream	Atopic Dermatitis	Ameliorated barrier integrity	Schempp et al. (2003)
TRPA1	Antagonist	HC-030031	Atopic Dermatitis		Oh et al. (2013)
TRPM8	Agonist	Thymol	Psoriasis	Attenuated the enhanced infiltration of dermal immune cells, downregulated expression of pro-inflammatory cytokines	Wang et al. (2020)